Status:

UNKNOWN

Application of a TBE-Vaccine in Obese Persons

Lead Sponsor:

Medical University of Vienna

Conditions:

Tick Borne Encephalitis

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

Obese people have an altered immune responsiveness. The present study investigates whether this influences immune responses to booster vaccinations (i. e. booster vaccination with TBE vaccine "FSME Im...

Detailed Description

Obese people have an altered immune responsiveness. Studies have shown that obesity has a direct effect on the immune system and leads to immunosuppression, which leads to a susceptibility to infectio...

Eligibility Criteria

Inclusion

  • main
  • willingness to sign written informed consent form
  • completed primary TBE immunization and at least 1 booster vaccination
  • participants of both sexes between 18 and 60 years of age
  • main

Exclusion

  • age \< 18 and \> 60 years
  • BMI 25-30
  • previous TBE infection
  • pregnancy or breast feeding
  • acute infection on day of inclusion (day 0) or at visit 5 (36 months), body temperature \> 37,9°C
  • concomitant medications: systemic cortison therapy, chemotherapy, immunotherapy (allergy) immunsuppressive therapy 4 weeks prior or during the study
  • administration of other vaccines 4 weeks before/after day 0
  • planned surgery within 2 weeks before/after TBE booster
  • any contraindication to administration of FSME-Immun® vaccine according to manufacturer's instructions
  • malignant diseases within 5 years prior to the study
  • autoimmune diseases
  • kidney insufficiency, dialysis
  • drug addiction
  • plasma donor
  • receipt of blood transfusions or immunoglobulins within 3 months prior to study entry / within 3 months prior to visit 5
  • Severe disease with hospitalization or surgery 3 months before or during the study
  • participation in a clinical trial simultaneously to visit 1-4 with receipt of vaccination and/or investigational product within one month before booster

Key Trial Info

Start Date :

April 15 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2020

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT04017052

Start Date

April 15 2015

End Date

December 30 2020

Last Update

September 10 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medical University Vienna, Institute of Specific Prophylaxis and Tropical Medicine

Vienna, Austria, 1090